Neil Brewis, Ph.D.Chief Scientific Officer at F-star Therapeutics
Neil Brewis has 20 years’ experience in antibody engineering and drug discovery and has successfully advanced novel platforms from inception to clinical proof of concept. He is CSO at F-star Therapeutics which is advancing multiple clinical-stage bispecific antibodies for the treatment of patients with cancer, and in particularly those who have resistance to other immuno-oncology medicines.
As Head of Biopharmaceutical Research at GSK, he played a role in growing the pipeline with antibodies, antibody fragments and recombinant protein therapeutics from concept to clinical development in a range of therapeutic areas. As VP, Head of Research, he played a major part in building the success of Domantis, a company focused on creating therapeutics using human domain antibodies and which was acquired by GSK in 2007. Neil has an Honorary Doctor of Science from Hertfordshire University. He holds a PhD in Biochemistry from Dundee University, Scotland.